Brazil's AI Fast-Track: Pure Global on Cracking ANVISA's 90-Day Approval Code. Podcast By cover art

Brazil's AI Fast-Track: Pure Global on Cracking ANVISA's 90-Day Approval Code.

Brazil's AI Fast-Track: Pure Global on Cracking ANVISA's 90-Day Approval Code.

Listen for free

View show details
This week on LATAM MedTech Insights, we dive into the seismic shift in Brazil's digital health market. ANVISA just launched its 'Agiliza-IA' program, promising to approve AI-powered diagnostic software in a record 90 days. This could unlock one of the largest markets in Latin America for SaMD innovators. But there's a catch. While the speed is tempting, the program introduces formidable new barriers. Consider a European company with a market-leading AI tool. They're ready to enter Brazil, but now face an unexpected demand for clinical trials conducted exclusively on Brazilian patients. This single requirement could delay their entry by a year and cost millions. Is the fast-track worth the price? Key Takeaways: - What exactly is ANVISA's new "Agiliza-IA" program? - Why are the new local clinical data requirements a game-changer for foreign companies? - What are the specific cybersecurity protocols you must now meet for approval? - How did a local startup beat global giants to the first approval? - Is Brazil's 90-day promise a real opportunity or a hidden trap? - What does this mean for the future of MedTech regulation across LATAM? - How can you start preparing your technical dossier for this new pathway today? At Pure Global, we specialize in turning these regulatory puzzles into market access victories. We offer end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your entry into over 30 global markets, including Brazil. Don't let complex regulations be a barrier to your growth. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/ to learn how we can accelerate your journey.
No reviews yet